Related Experiment Video
Updated: Jul 10, 2026

Mapping Hepatic Stellate Cell Morphology in Mouse Models of Liver Fibrosis
Published on: February 13, 2026
The utility of STRIATIN as a novel diagnostic marker in cirrhosis
Balasubramaniyan Vairappan1, Vigneshwaran Venkatesan1, Pazhanivel Mohan2
1Liver Diseases Research Lab, Department of Biochemistry, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Pondicherry 605006, India.
Background:
Endothelial dysfunction and endothelial nitric oxide synthase (eNOS) mediated reduction in nitric oxide (NO) bioavailability are pivotal in the pathogenesis of portal hypertension (PHT) associated with liver cirrhosis. Striatin, a scaffolding protein that regulates eNOS activation, may play a crucial but unexplored role in this context. This study aimed to investigate hepatic striatin expression and its association with eNOS in cirrhosis, assess systemic striatin concentrations in cirrhotic patients, and evaluate its potential as a diagnostic biomarker for PHT.
Materials And Methods:
A case-control study was conducted including 40 cirrhotic patients and 40 age- and sex-matched healthy controls. Hepatic striatin and phosphorylccated eNOS (peNOS) expressions were determined by Western blotting. Serum striatin and cyclic guanosine monophosphate (cGMP) concentrations were measured using ELISA, and biochemical parameters were analyzed using a Beckman Coulter AU 680 autoanalyzer.
Results:
Serum striatin levels were significantly lower in cirrhotic patients than in controls (6.86 ± 1.7 vs. 10.9 ± 1.7 ng/ml; P < 0.0001). Conversely, serum cGMP levels were significantly higher in cirrhotic patients (10.90 ± 2.8 vs. 5.19 ± 2.3 pmol/ml; P < 0.0001), with no correlation observed between striatin and cGMP concentrations. Hepatic striatin expression was markedly reduced in cirrhotic livers and positively correlated with peNOS levels. Receiver operating characteristic (ROC) analysis demonstrated that serum striatin had superior diagnostic accuracy compared with cGMP for distinguishing cirrhotic patients from controls.
Conclusions:
Both systemic and hepatic striatin levels are significantly reduced in cirrhosis, suggesting a potential role of striatin downregulation in endothelial dysfunction and PHT. Striatin may serve as a promising diagnostic biomarker for cirrhotic patients with PHT. Further studies are warranted to elucidate the therapeutic potential of the striatin-eNOS-NO signaling axis in advanced cirrhosis.
Related Concept Videos
Ultrasound II: Endoscopic Ultrasound and FibroScan
Endoscopic Ultrasound (EUS):
Cirrhosis II: Pathophysiology
Cirrhosis I: Introduction
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Serum Laboratory Studies, Stool Test, Breath Test